IntegraGen SA (ALINT.PA)

EUR 0.53

(0.0%)

Operating Income Summary of IntegraGen SA

  • IntegraGen SA's latest annual operating income in 2023 was -183.77 Thousand EUR , down -67.34% from previous year.
  • IntegraGen SA's latest quarterly operating income in 2024 Q2 was -679 Thousand EUR , down 0.0% from previous quarter.
  • IntegraGen SA reported an annual operating income of -109.82 Thousand EUR in 2022, down -271.64% from previous year.
  • IntegraGen SA reported an annual operating income of -29.55 Thousand EUR in 2021, up 82.85% from previous year.
  • IntegraGen SA reported a quarterly operating income of -422.73 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • IntegraGen SA reported a quarterly operating income of -183.77 Thousand EUR for 2023 FY, down -67.34% from previous quarter.

Annual Operating Income Chart of IntegraGen SA (2023 - 2008)

Historical Annual Operating Income of IntegraGen SA (2023 - 2008)

Year Operating Income Operating Income Growth
2023 -183.77 Thousand EUR -67.34%
2022 -109.82 Thousand EUR -271.64%
2021 -29.55 Thousand EUR 82.85%
2020 -172.33 Thousand EUR 52.53%
2019 -363 Thousand EUR 69.22%
2018 -1.17 Million EUR 38.9%
2017 -1.93 Million EUR -8.51%
2016 -1.77 Million EUR 23.12%
2015 -2.31 Million EUR -37.23%
2014 -1.68 Million EUR 41.72%
2013 -2.89 Million EUR -22.19%
2012 -2.36 Million EUR 1.43%
2011 -2.4 Million EUR 14.46%
2010 -2.8 Million EUR 1.01%
2009 -2.83 Million EUR -7.21%
2008 -2.64 Million EUR 0.0%

Peer Operating Income Comparison of IntegraGen SA

Name Operating Income Operating Income Difference
ABIONYX Pharma SA -3.41 Million EUR 94.614%
ABIVAX Société Anonyme -127.37 Million EUR 99.856%
Adocia SA -17.62 Million EUR 98.957%
Aelis Farma SA -6.46 Million EUR 97.156%
Biophytis S.A. -14.33 Million EUR 98.718%
Advicenne S.A. -6.45 Million EUR 97.154%
genOway Société anonyme 2.06 Million EUR 108.898%
Medesis Pharma S.A. -4.22 Million EUR 95.655%
Neovacs S.A. -6.9 Million EUR 97.34%
NFL Biosciences SA -4.43 Million EUR 95.852%
Plant Advanced Technologies SA -778.23 Thousand EUR 76.386%
Quantum Genomics Société Anonyme -3.13 Million EUR 94.142%
Sensorion SA -22.31 Million EUR 99.176%
Theranexus Société Anonyme -7.64 Million EUR 97.596%
TME Pharma N.V. -5.62 Million EUR 96.732%
Valbiotis SA -7.16 Million EUR 97.433%
TheraVet SA -2.17 Million EUR 91.551%
Valerio Therapeutics Société anonyme -20.28 Million EUR 99.094%
argenx SE -417.15 Million EUR 99.956%
BioSenic S.A. -7.04 Million EUR 97.39%
Celyad Oncology SA -8.45 Million EUR 97.827%
DBV Technologies S.A. -85.24 Million EUR 99.784%
Galapagos NV -88.26 Million EUR 99.792%
Genfit S.A. -26.58 Million EUR 99.309%
GeNeuro SA -14.35 Million EUR 98.72%
Hyloris Pharmaceuticals SA -15.99 Million EUR 98.851%
Innate Pharma S.A. -12.66 Million EUR 98.549%
Inventiva S.A. -102.7 Million EUR 99.821%
MaaT Pharma SA -19.94 Million EUR 99.079%
MedinCell S.A. -20.97 Million EUR 99.124%
Nanobiotix S.A. -26.77 Million EUR 99.314%
Onward Medical N.V. -35.46 Million EUR 99.482%
Oryzon Genomics S.A. -4.54 Million EUR 95.96%
OSE Immunotherapeutics SA -22.98 Million EUR 99.201%
Oxurion NV -12.11 Million EUR 98.482%
Pharming Group N.V. -4.87 Million EUR 96.234%
Poxel S.A. -28.76 Million EUR 99.361%
GenSight Biologics S.A. -29.69 Million EUR 99.381%
Transgene SA -30.01 Million EUR 99.388%
Financière de Tubize SA -2.14 Million EUR 91.429%
UCB SA 604 Million EUR 100.03%
Valneva SE -82.08 Million EUR 99.776%
Vivoryon Therapeutics N.V. -28.83 Million EUR 99.363%